{"id":"W2144939065","doi":"10.1016/j.jacc.2012.02.008","title":"New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes","year":2012,"lang":"en","type":"review","venue":"Journal of the American College of Cardiology","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":267,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University","funders":"Schering-Plough; Roche; GlaxoSmithKline; Pfizer","keywords":"Medicine; Rivaroxaban; Apixaban; Edoxaban; Dabigatran; Atrial fibrillation; Warfarin; Stroke (engine); Cardiology; Internal medicine; Direct thrombin inhibitor; Anesthesia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001091151,0.0006972071,0.002553184,0.00327848,0.0002622286,0.0009987097,0.0007905207,0.001286656,0.004015012],"category_scores_gemma":[0.0032598,0.0003620122,0.001256942,0.003149826,0.0003374736,0.001102222,0.0006401486,0.001408997,0.0005430841],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005059273,"about_ca_system_score_gemma":0.001339459,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001996993,"about_ca_topic_score_gemma":0.005729299,"domain_scores_codex":[0.9994082,0.00009238748,0.0001893621,0.00007430916,0.0002051622,0.00003056942],"domain_scores_gemma":[0.998316,0.0007740239,0.0006100081,0.00002348267,0.0002061634,0.00007033186],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000256934,0.0001417954,0.001594675,0.05780816,0.001129224,0.0002324572,0.00005238058,0.0001733746,0.0003958293,0.0007883962,0.02471789,0.912709],"study_design_scores_gemma":[0.0009403472,0.000907652,0.02290954,0.08783937,0.01435132,0.005040305,0.0002756751,0.0005615584,0.000603219,0.002740493,0.8637127,0.0001177837],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001274549,0.9992657,0.00003002546,0.0001455481,0.0001413713,0.00000390048,0.00001549372,0.000002216069,0.0002682219],"genre_scores_gemma":[0.001428223,0.9977017,0.0001164846,0.0002539334,0.0002970593,0.00000810723,0.00002772547,4.939889e-7,0.0001663604],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004015012,"threshold_uncertainty_score":0.01343149,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09045453171110361,"score_gpt":0.3783420554777537,"score_spread":0.2878875237666501,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}